Physician profile
Ajit Naidu
NPI 1912904913
$66,093.39
in general payments reported to CMS, 2019-2025
21 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $210 · 2021: $423 · 2022: $256 · 2023: $158 · 2024: $138 · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $64K · Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $63,700.00 |
| Food and Beverage | $491.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $63,740.34 | 2024-2025 | |
| Boston Scientific Corporation | $914.67 | 2019-2025 | Varithena Administration Pack |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.45 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $190.42 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Venclose INC. | $156.38 | 2020 | |
| Bard Peripheral Vascular, INC. | $119.40 | 2021-2022 | |
| Medtronic, INC. | $118.13 | 2021-2024 | Venaseal |
| Revance Therapeutics, INC. | $97.84 | 2025 | Daxxify |
| Novo Nordisk INC | $72.74 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $62.67 | 2019-2024 | |
| Amgen INC. | $56.17 | 2019-2021 | |
| Biocompatibles, INC. | $52.96 | 2019 | |
| Philips North America LLC | $33.14 | 2024 | (Cm9) Amb Mon & Diag Und |
| Angiodynamics, INC. | $30.29 | 2021-2024 | Auryon Laser System 100-120 Vac |
| Medtronic Vascular, INC. | $24.84 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.15 | 2025 | Camzyos |
| Organogenesis INC. | $16.50 | 2019 | |
| Tactile Systems Technology INC | $14.98 | 2019 | |
| Lilly USA, LLC | $14.66 | 2023 | Mounjaro |
| Triad Life Sciences INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajit Naidu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.